Bausch Health Reports 13% Revenue Growth to $2.85 Billion in Q2 2026

Bausch Health Companies Inc. reported significant financial results for the second quarter of 2026, with revenues reaching $2.85 billion, a 13% increase from $2.53 billion in the same period last year. The growth was primarily driven by improved net realized pricing, incremental sales from acquisitions, and favorable foreign currency impacts. The Salix segment, which includes the Xifaxan® product line, contributed notably to this increase, with revenues rising to $758 million, up 21% year-over-year. However, the company also faced challenges, including lower volumes and the impact of divestitures.

Despite the revenue growth, Bausch Health experienced an operating loss of $210 million for the first half of 2026, compared to an operating income of $720 million in the prior year. This decline was largely attributed to a substantial goodwill impairment charge of $1.43 billion related to the Salix reporting unit, following disappointing results from clinical trials for its rifaximin formulation. The net loss attributable to Bausch Health for the six months ended June 30, 2026, was $1.17 billion, a stark contrast to the net income of $90 million reported in the same period of 2025.

Strategically, Bausch Health has been active in acquisitions, including the purchase of Wuhan Shibo Zhenmei Technology Co., Ltd. in December 2025, which expanded its distribution capabilities in China. The company also acquired DURECT Corporation, focusing on developing therapies for alcohol-associated hepatitis. These acquisitions are part of Bausch Health's broader strategy to enhance its core business segments and drive future growth.

Operationally, the company reported a total employee headcount of approximately 14,000 as of June 30, 2026, reflecting ongoing efforts to streamline operations and improve efficiency. The company continues to evaluate its capital structure and has made significant progress in managing its debt, with total long-term debt standing at $20.74 billion as of the end of June 2026. Bausch Health expects to remain compliant with its financial covenants and meet its debt service obligations in the coming year.

Looking ahead, Bausch Health remains focused on executing its business strategy, which includes the potential separation of its eye health business, Bausch + Lomb, into an independent entity. The company anticipates that this separation could unlock additional value, although it acknowledges the inherent risks and uncertainties involved. Management is committed to improving operational efficiencies and enhancing patient access to its products, while also navigating the challenges posed by market conditions and regulatory changes.